Kezar Life Sciences, Inc. (KZR) Cash & Equivalents (2017 - 2026)

Kezar Life Sciences has reported Cash & Equivalents for 10 years, with the latest figure at $66.2 million in Q1 2026.

• Quarterly Cash & Equivalents rose 78.99% year-over-year to $66.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.2 million (up 78.99% YoY) and the FY2025 annual result came in at $71.9 million, up 72.17% from the prior year.
• Cash & Equivalents retreated to $66.2 million in Q1 2026 per KZR's latest filing, from $71.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $105.4 million in Q2 2022 and troughed at $26.5 million in Q3 2023.
• A 5-year average of $44.8 million and a median of $37.0 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents soared 299.47% in 2022, then tumbled 73.33% in 2023.
• Over 5 years, Cash & Equivalents stood at $40.5 million in 2022, then dropped by 12.27% to $35.5 million in 2023, then grew by 17.63% to $41.7 million in 2024, then soared by 72.17% to $71.9 million in 2025, then dropped by 7.86% to $66.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $66.2 million, $71.9 million, and $38.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.